Closely similar tacrolimus morning troughs and graft function across the recipients' common ABCB1 polymorphisms (c.2677G>T/A, c.1236C>T, c.3435C>T) early after renal transplantation [0.03%]
肾移植早期同种异体ABCB1多态性（c.2677G>T / A，c.1236C>T，c.3435C>T）受者中的他克莫司早晨谷浓度和移植物功能的密切相关性
Luka Penezić,Sandra Nađ Škegro,Lana Ganoci et al.
Luka Penezić et al.
Background: Reports about relevance of three common and linked ABCB1 polymorphisms (c.2677G>T/A, c.1236C>T, c.3435C>T) for exposure to- and functional outcomes in tacrolimus-treated renal transplant patients are inconsist...
Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use [0.03%]
用于抑郁症分层抗抑郁治疗的药物基因组学：证据、局限性和临床应用路线图
Bernhard T Baune
Bernhard T Baune
Major depressive disorder (MDD) is treated largely by trial and error, despite marked interindividual variation in antidepressant exposure, efficacy and tolerability. Pharmacogenomics (PGx) has therefore been proposed as a route to stratifi...
Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type" [0.03%]
知情公众关于采集和分享抑郁症药物基因组学检测结果的指导意见：“这与你的血型没有区别”
Colene Bentley,Louisa Edwards,Kieran C O&#x;Doherty et al.
Colene Bentley et al.
Introduction: Many people with major depressive disorder (MDD) undergo a lengthy process of trial-and-error before finding a medication that works well for them. Pharmacogenomic (PGx) testing for MDD can help find a suita...
Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models [0.03%]
临床服务输送模型下的药物基因组学流程优化：定性评估
Emily Huang,Aniwaa Owusu Obeng,Scott A Stuart et al.
Emily Huang et al.
Despite the promise of personalized medicine, the clinical implementation of pharmacogenomics (PGx) remains limited. Several barriers limiting implementation of PGx have been identified, some of which include provider awareness, uncertainty...
Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases [0.03%]
单基因预测与人工智能驱动的多基因精确诊疗在心血管疾病中的联合应用
Navakanth Raju Ramayanam,Sarad Pawar Naik Bukke,Chandrashekar Thalluri et al.
Navakanth Raju Ramayanam et al.
Pharmacogenomics (PGx) is transforming how we treat cardiovascular disease (CVD) by enabling us to select and dose drugs based on our genetic profiles. The pharmacokinetics and pharmacodynamics of commonly prescribed cardiovascular drugs ar...
Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care [0.03%]
儿科肿瘤学常规护理中实施预置型药物基因筛查的实践指南
Emma C Bernsen,Lidwien M Hanff,Theodorus W Kouwenberg et al.
Emma C Bernsen et al.
Interindividual variability in drug response is a challenge in pediatric oncology, where the risk of treatment-related toxicity is exacerbated by narrow therapeutic windows and combination therapies. Pharmacogenetics (PGx) aims to reduce th...
Reduction of next-generation sequencing files for efficient pharmacogenotype extraction [0.03%]
高效药物基因型提取的下一代测序文件精简
Hargoon N Kaur,Reynold C Ly,Steven M Bray et al.
Hargoon N Kaur et al.
Objectives: The most comprehensive computational pharmacogenotype extraction methods utilize Binary Alignment/Map (BAM) files, which require intensive storage resources. The pharmacogenotyping tool Aldy, which has been va...
Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapy [0.03%]
DPYD和UGT1A1指导的化疗药物临床应用考量
Mary-Pearl Ojukwu,Carlos Vegas,Emily J Cicali et al.
Mary-Pearl Ojukwu et al.
Existing literature demonstrates the benefits of DPYD and UGT1A1 pharmacogenetic (PGx) testing to reduce toxicity from fluoropyrimidines and irinotecan, respectively. The Food and Drug Administration (FDA) has provided UGT1A1-guided irinote...
Genetics of tardive dyskinesia: a review of progress over the past decade [0.03%]
迟发性运动障碍的遗传学：过去十年的研究进展回顾
Clement C Zai,Megana Thamilselvan,Francesca Chernous et al.
Clement C Zai et al.
Tardive dyskinesia (TD) is a potentially irreversible movement disorder that emerges in a proportion of schizophrenia patients who are prescribed antipsychotic medications. These movements affect mostly the orofacial regions, but may also a...
Long non-coding RNAs and survival outcomes in chronic lymphocytic leukemia [0.03%]
长链非编码RNA与慢性淋巴细胞白血病预后的关系
Teodora Karan-Djurasevic,Irena Marjanovic,Natasa Tosic
Teodora Karan-Djurasevic
Chronic lymphocytic leukemia (CLL) is a highly heterogeneous hematological malignancy characterized by pronounced differences in clinical course and genetic background. While research has historically focused on alterations in protein-codin...